Edoxaban Versus Edoxaban With antiPlatelet Agent In Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1040 participants.

Also called NCT03718559

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,040 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03718559
Other papers using this trial's data
  • Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease The New England journal of medicine, 2024-12-05 DOI, PubMed 39225258
  • Edoxaban antithrombotic therapy in diabetic patients with atrial fibrillation and stable coronary artery disease: the EPIC-CAD trial Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2026-10-01 DOI, PubMed 42690164, PMC13646602 In the PMC Open Access subset under CC BY-NC.
  • Impact of Atrial Fibrillation Pattern on Edoxaban Antithrombotic Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease: A Secondary Analysis of the EPIC-CAD Randomized Clinical Trial Journal of the American Heart Association, 2026-04-07 DOI, PubMed 41848064, PMC13279072 In the PMC Open Access subset under CC BY-NC-ND.
  • Impact of renal function on edoxaban antithrombotic therapy in patients with atrial fibrillation and stable coronary artery disease: a prespecified analysis of the EPIC-CAD trial EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2026-04-20 DOI, PubMed 42003300, PMC13080388 Not in the PMC Open Access subset.
  • Off-label underdosing of edoxaban antithrombotic therapy for patients with atrial fibrillation and stable coronary artery disease: findings from the EPIC-CAD trial Heart (British Cardiac Society), 2026-03-12 DOI, PubMed 40930594

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03718559. Randomized; no masking; primary purpose treatment. Start 2019-05-14 (actual); primary completion 2023-11-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Edoxaban Versus Edoxaban With antiPlatelet Agent In Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease
Acronym
EPIC-CAD
Condition
Stable Angina
Condition
Stable Chronic Angina
Intervention (Drug)
Edoxaban Monotherapy
Intervention (Drug)
Edoxaban plus Single Antiplatelet Agent
Lead sponsor
Gi-Byoung Nam (class: other)
Collaborator
CardioVascular Research Foundation, Korea (class: other)

Record details

Record id
cardio:ct-nct03718559
Content hash
2deba71b9b314a7e309832adbccbd67fdf98d934c2bbc2dcd10e81d1136ae007